TY  - JOUR
AU  - Stahl, Maximilian
AU  - DeVeaux, Michelle
AU  - Montesinos, Pau
AU  - Itzykson, Raphael
AU  - Ritchie, Ellen K
AU  - Sekeres, Mikkael A
AU  - Barnard, John D
AU  - Podoltsev, Nikolai A
AU  - Brunner, Andrew M
AU  - Komrokji, Rami S
AU  - Bhatt, Vijaya R
AU  - Al-Kali, Aref
AU  - Cluzeau, Thomas
AU  - Santini, Valeria
AU  - Fathi, Amir T
AU  - Roboz, Gail J
AU  - Fenaux, Pierre
AU  - Litzow, Mark R
AU  - Perreault, Sarah
AU  - Kim, Tae Kon
AU  - Prebet, Thomas
AU  - Vey, Norbert
AU  - Verma, Vivek
AU  - Germing, Ulrich
AU  - Bergua, Juan Miguel
AU  - Serrano, Josefina
AU  - Gore, Steven D
AU  - Zeidan, Amer M
PY  - 2018
DO  - 10.1182/bloodadvances.2018016121
UR  - http://hdl.handle.net/10668/12380
T2  - Blood advances
AB  - Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about their effectiveness in relapsed or primary treatment-refractory (RR)-AML. Using an...
LA  - en
PB  - American Society of Hematology
KW  - Myeloid Neoplasia
KW  - Clinical Trials and Observations
KW  - Antimetabolitos antineoplásicos
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antimetabolites, Antineoplastic
KW  - Cohort Studies
KW  - DNA Methylation
KW  - Databases, Factual
KW  - Decitabine
KW  - Humans
KW  - Leukemia, Myeloid, Acute
KW  - Middle Aged
KW  - Prognosis
KW  - Remission Induction
KW  - Retrospective Studies
KW  - Salvage Therapy
KW  - Survival Analysis
KW  - Treatment Outcome
KW  - Young Adult
TI  - Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.
TY  - research article
VL  - 2
ER  -